GNI Group Completes Acquisition of AYUMI Pharmaceutical

GNI Group Ltd. has completed its acquisition of Ayumi Pharmaceutical Holdings Co., Ltd. from Blackstone and other shareholders for approximately JPY 44.8 billion. The acquisition marks GNI Group's entry into Japan's pharmaceutical market, establishing what the company calls its 'Second Founding Phase' as a global biopharma company. Ayumi Pharmaceutical, with JPY 38.5 billion in annual revenue and over 80% market share in acetaminophen products, will operate as a wholly owned subsidiary while maintaining its brand names and product portfolio.